The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials

BackgroundOrally effective therapeutics for plaque psoriasis with improved response rates, lower toxicity and costs are needed in clinical practices. This study aims to assess the efficacy and safety of the recently approved TYK2 inhibitor deucravacitinib in adults with moderate to severe plaque pso...

Full description

Bibliographic Details
Main Authors: Jingyue Qiu, Jiakuo Liu, Wenwen Liu, Fei Lin, Ning Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Medicine
Subjects:
TYK2 inhibitor
deucravacitinib
psoriasis
autoimmune disease
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1264667/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1264667/full

Similar Items